Market: NMS |
Currency: USD
Address: 311 West Superior Street
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
📈 Cardio Diagnostics Holdings, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-05-15
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Cardio Diagnostics Holdings, Inc.
| Date | Reported EPS |
|---|
| 2026-05-14 (estimated upcoming) | - |
| 2025-05-15 | -0.97 |
| 2025-03-20 | -0.3 |
| 2024-11-13 | -1.8 |
| 2024-08-12 | -1.8 |
| 2024-05-15 | -6 |
| 2024-04-01 | -31.89 |
| 2023-11-13 | -5.08 |
| 2023-08-14 | -10.72 |
| 2023-05-15 | 14.63 |
| 2023-03-31 | -0.69 |
| 2022-11-07 | 0.6 |
📰 Related News & Research
🔍 View more Reports
